N,O-1,3-二乙酰基吲哚 | 16800-67-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N,O-1,3-二乙酰基吲哚
• 中文别名: 1-乙酰基-1H-吲哚-3-基乙酸酯
• 英文名称: N,O-diacetylindoxyl
• 英文别名: 1-acetyl-1H-indol-3-yl acetate；O,N-diacetylindoxyl；O,N-acetylindoxyl；3-acetoxy-1-acetylindole；(1-acetylindol-3-yl) acetate
• CAS: 16800-67-2
• 化学式: C₁₂H₁₁NO₃
• mdl: MFCD00022890
• 分子量: 217.224
• InChiKey: DNVFBLDIZKYQPL-UHFFFAOYSA-N

物化性质

• 熔点：
  80 °C
• 沸点：
  345.3±15.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 储存条件：
  | -20°C |

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Indoxyl 1,3-diacetate
CAS-No. : 16800-67-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 1,3-Diacetoxyindole
Formula : C12H11NO3
Molecular Weight : 217,22 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

N,O-1,3-二乙酰基吲哚是一种有机中间体，有文献报道其可用于制备11-β-羟基类固醇脱氢酶的抑制剂。

制备

2-[(羧甲基)氨基]苯甲酸(中间体-32)的合成：

向装备有磁力搅拌器的500 mL双颈RB烧瓶中，加入K₂CO₃（83 g，602 mmol）并搅拌溶解在水（140 mL）中。然后，在室温下氮气保护下缓慢滴加邻氨基苯甲酸（20 g，145 mmol），接着滴加氯乙酸（13.7 g，145 mmol），约30分钟。随后，在90 ℃下加热反应物16小时。冷却至室温后，使用柠檬酸将反应物料pH值调节至4-5。过滤固体物质，并在70 ℃的真空炉中干燥12小时，最终获得淡褐色固体中间体-32（23 g）。

N,O-1,3-二乙酰基吲哚(中间体-33)的合成：

向装备有磁力搅拌器的500 mL双颈RB烧瓶中，在0 ℃氮气保护下，加入三乙胺（170 mL，1242 mmol）和中间体-32（23 g，117 mmol），然后在搅拌溶液中缓慢添加乙酸酐（110 mL，1200 mmol）。室温下搅拌反应物料5小时，并进一步于80 ℃加热16小时。冷却至0 ℃后，用乙酸乙酯（4×150 mL）萃取有机层。使用盐水溶液洗涤有机层，在Na₂SO₄上干燥并浓缩。通过硅胶柱洗脱纯化粗料，最终获得呈褐色固体的中间体-33（5.5 g）。

反应信息

• 作为反应物：
  描述：

  N,O-1,3-二乙酰基吲哚 在 乙酸铵 、 sodium hydroxide 、 水 、 sodium sulfite 、 xylene 、 苯酚 作用下， 生成 3-吲哚乙酸
  参考文献：
  名称：

  Nenitzescu; Raileanu, Chemische Berichte, 1958, vol. 91, p. 1141,1143

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴苯甲酸 在 乙酸酐 、 铜 、 potassium carbonate 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 17.0h， 生成 N,O-1,3-二乙酰基吲哚
  参考文献：
  名称：

  靛玉红衍生物作为靶向细胞周期蛋白依赖性激酶和组蛋白脱乙酰酶的双重抑制剂用于治疗癌症

  摘要：

  为了利用天然产物靛玉红的独特支架，我们在此采用组合药效团的策略来设计和合成一系列新型靛玉红衍生物，作为针对细胞周期蛋白依赖性激酶 (CDK) 和组蛋白脱乙酰酶 (HDAC) 的双重抑制剂。其中，先导化合物8b具有显着的CDK2/4/6和HDAC6抑制活性，IC 50 = 60.9 ± 2.9、276 ± 22.3、27.2 ± 4.2和128.6 ± 0.4 nM，可有效诱导细胞凋亡和S期在几种癌细胞系中停滞。特别是化合物8b可以通过 Mcl-1/XIAP/PARP 轴阻止非小细胞肺癌细胞系 (A549) 的增殖，这与 HDAC 抑制剂和 CDK 抑制剂联合药物的独特作用模式一致。在 A549 静电复印机模型中，化合物8b显示出与其双重抑制相关的显着抗肿瘤功效。我们的数据表明，化合物8b作为单一药物可能是与 CDK 和 HDAC 抑制剂联合用于癌症治疗的有希望的候选药物。

  DOI：

  10.1021/acs.jmedchem.1c01311
• 作为试剂：
  描述：

  吲哚乙酸酯 、 乙酸酐 、 三乙胺 、 在 4-二甲氨基吡啶 乙酸乙酯 、 氯化钠 、 Sodium sulfate-III 、 petroleum ether ethyl acetate 、 N,O-1,3-二乙酰基吲哚 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以This resulted in 6.6 g (67%) of 1-acetyl-1H-indol-3-yl acetate as a white solid的产率得到N,O-1,3-二乙酰基吲哚
  参考文献：
  名称：

  Compounds having 5-HT6 receptor affinity

  摘要：

  本公开提供具有亲和力的化合物，其对5HT6受体具有亲和力，其化学式为(I)：其中R1-R3，A，B，D，E，G，Q和x的定义如本文所述。本公开还涉及制备这种化合物的方法，包含这种化合物的组合物以及使用它们的方法。

  公开号：

  US07696229B2

文献信息

• CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150158860A1

  公开（公告）日：2015-06-11

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防和治疗可以通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其他疾病和状况中找到应用。
• [EN] CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMIDE CYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE ET UTILISATIONS DE CEUX-CI
  申请人：CONNEXIOS LIFE SCIENCES PVT LTD

  公开号：WO2013128465A1

  公开（公告）日：2013-09-06

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，本发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将用于治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其它疾病和状况。
• <i>N</i>-Heterocyclic Carbene-Catalyzed Enantioselective Annulation of Indolin-3-ones with Bromoenals
  作者：Qijian Ni、Xiaoxiao Song、Gerhard Raabe、Dieter Enders

  DOI：10.1002/asia.201402052

  日期：2014.6

  N‐Heterocyclic carbene‐catalyzed reactions of indolin‐3‐ones with 2‐bromoenals opened an asymmetric access to 3,4‐dihydropyrano[3,2‐b]indol‐2(5 H)‐ones in good yields and with good to excellent enantioselectivities. This protocol tolerates a broad substrate scope. In addition, a possible mechanism for the annulation reaction is presented.

  吲哚-3-酮与2-溴烯的N杂环卡宾催化的反应打开了3,4-二氢吡喃[3,2 -b ]吲哚-2（5  H）酮的不对称通道，收率高且优异的对映选择性。该协议可容忍广泛的基材范围。此外，提出了一种可能的环化反应机理。
• Synthesis and Biological Evaluation of Analogues of Cryptolepine, an Alkaloid Isolated from the Suriname Rainforest
  作者：Shu-Wei Yang、Maged Abdel-Kader、Stan Malone、Marga C. M. Werkhoven、Jan H. Wisse、Isia Bursuker、Kim Neddermann、Craig Fairchild、Carmen Raventos-Suarez、Ana T. Menendez、Kate Lane、David G. I. Kingston

  DOI：10.1021/np990035g

  日期：1999.7.1

  Bioassay-guided fractionation of an extract of a mixture of Microphilis guyanensis and Genipa americanacollected in the rainforest of Suriname yielded the known alkaloid cryptolepine (2) as the major active compound in a yeast bioassay for potential DNA-damaging agents; the same compound was later reisolated from M. guyanensis. The structure of cryptolepine was identified unambiguously by spectral

  在苏里南雨林中收集的圭亚非球藻和美洲Genipa混合物的提取物的生物测定指导分级分离，产生了已知的生物碱隐氯品（2），它是酵母生物测定中潜在的潜在DNA破坏剂的主要活性化合物。相同的化合物后来从圭亚那分支杆菌中分离出来。通过光谱数据及其全部合成，明确鉴定了隐肾上腺素的结构。基于对C-2，N-5，N-10和C-11位置的修饰，合成了几种隐肾上腺素衍生物（3-29、32-41）。还制备了两个隐肾上腺素二聚体（30、31）。尽管某些衍生物确实显示出显着的活性，但在酵母分析系统中，结构修饰并未产生比母体化合物隐氯平具有更高效力的化合物。选定的化合物（6、7、17、22、23、26，
• The “Gatekeeper” Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains
  作者：Andrea Unzue、Hongtao Zhao、Graziano Lolli、Jing Dong、Jian Zhu、Melanie Zechner、Aymeric Dolbois、Amedeo Caflisch、Cristina Nevado

  DOI：10.1021/acs.jmedchem.5b01757

  日期：2016.4.14

  hopping followed by docking of a set of ∼200 compounds containing the acetyl indole scaffold. Chemical synthesis of nearly 30 derivatives has resulted in ligands of representatives of three subfamilies of human bromodomains with favorable ligand efficiency. The X-ray crystal structures of three different bromodomains (CREBBP, BAZ2B, and BRPF1b) in complex with acetyl indole derivatives reveal the influence

  CREBBP和BAZ2B溴结构域的小分子命中已通过支架跳跃鉴定，然后对接约200种含乙酰基吲哚支架的化合物。近30种衍生物的化学合成产生了具有良好配体效率的人类溴结构域的三个亚家族的代表配体。三种不同的溴结构域（CREBBP，BAZ2B和BRPF1b）与乙酰基吲哚衍生物复合的X射线晶体结构揭示了关守残基对乙酰基赖氨酸结合位点中小分子配体取向的影响。